Next Science (ASX:NXS), an innovative medical technology company and leader in treating biofilm-based infections in humans, today announced new educational broadcast content about chronic infections, which impact 17 million Americans each year. “The Balancing Act,” a lifestyle show that airs on the Lifetime channel, will feature a segment that discusses the costly and debilitating nature of these infections and how physicians can more effectively treat patients suffering from chronic wounds, including diabetic wounds, by using BLASTX, Next Science’s antimicrobial wound gel … In addition to treating diabetic foot and leg ulcers, BLASTX can also be used for stage I-V pressure ulcers, partial- and full-thickness wounds, post-surgical wounds, first and second degree burns, and grafted and donor sites. BLASTX, which uses Next Science’s patented XBIO® Technology, which physically deconstructs the protective shell over the bacterial biofilm matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. BLASTX is non-toxic and lasts up to five days … read more